Literature DB >> 20946861

Herpes zoster: Burden of disease in France.

S Gonzalez Chiappe1, M Sarazin, C Turbelin, A Lasserre, C Pelat, I Bonmarin, O Chosidow, T Blanchon, T Hanslik.   

Abstract

This work provides estimates of HZ incidence and HZ-related hospitalization and mortality rates in France, where no immunization programme has been implemented. Herpes zoster data was obtained from the Sentinelles surveillance general practitioners (GPs) network, the PMSI Data processing centre for hospital discharges and from the French National Mortality Database (INSERM CépiDC). The yearly HZ incidence rate averaged 382 cases per 100,000 inhabitants (95% CI 364-405) and exponentially increased with age. The annual rates of hospitalizations and mortality due to HZ varied from 4.14±0.32 to 14.42±0.39 and from 0.11±0.03 to 0.29±0.04 per 100,000 inhabitants, respectively, depending on whether HZ was coded in a 'primary' or 'primary or associated' diagnosis. One or more factors of immunodepression occurred in 43.4% of hospitalized cases and in 21.6% HZ-related deaths.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Mesh:

Year:  2010        PMID: 20946861     DOI: 10.1016/j.vaccine.2010.09.074

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011.

Authors: 
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

Review 2.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

3.  A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China.

Authors:  Li Lu; Luodan Suo; Juan Li; Xinghuo Pang
Journal:  Hum Vaccin Immunother       Date:  2018-07-30       Impact factor: 3.452

4.  The Epidemiology of Herpes Zoster After Varicella Immunization Under Different Biological Hypotheses: Perspectives From Mathematical Modeling.

Authors:  Giorgio Guzzetta; Piero Poletti; Stefano Merler; Piero Manfredi
Journal:  Am J Epidemiol       Date:  2016-03-18       Impact factor: 4.897

5.  Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.

Authors:  Emmanuel Belchior; Daniel Lévy-Bruhl; Yann Le Strat; Magid Herida
Journal:  Hum Vaccin Immunother       Date:  2016-08-02       Impact factor: 3.452

6.  A systematic literature review of herpes zoster incidence worldwide.

Authors:  Désirée van Oorschot; Hilde Vroling; Eveline Bunge; John Diaz-Decaro; Desmond Curran; Barbara Yawn
Journal:  Hum Vaccin Immunother       Date:  2021-03-02       Impact factor: 3.452

7.  Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study.

Authors:  B Liu; A E Heywood; J Reekie; E Banks; J M Kaldor; P McIntyre; A T Newall; C R Macintyre
Journal:  Epidemiol Infect       Date:  2015-01-16       Impact factor: 4.434

8.  Herpes zoster in Germany: quantifying the burden of disease.

Authors:  Bernhard Ultsch; Anette Siedler; Thorsten Rieck; Thomas Reinhold; Gérard Krause; Ole Wichmann
Journal:  BMC Infect Dis       Date:  2011-06-16       Impact factor: 3.090

Review 9.  Similar herpes zoster incidence across Europe: results from a systematic literature review.

Authors:  Sybil Pinchinat; Ana M Cebrián-Cuenca; Hélène Bricout; Robert W Johnson
Journal:  BMC Infect Dis       Date:  2013-04-10       Impact factor: 3.090

Review 10.  A systematic review of the cost effectiveness of herpes zoster vaccination.

Authors:  Thomas D Szucs; Alena M Pfeil
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.